Anticholinergic Burden in Children, Adults and Older Adults in Slovenia: A Nationwide Database Study

Scientific Reports - Tập 10 Số 1
Nanča Čebron Lipovec1, Janja Jazbar1, Mitja Kos1
1University of Ljubljana, Faculty of Pharmacy, Ljubljana 1000, Slovenia

Tóm tắt

AbstractAnticholinergic burden has been widely studied in specific patient populations with specific conditions. However, the prevalence in the general population is poorly understood. This retrospective cross-sectional study was a nationwide database analysis of outpatient prescriptions of anticholinergic medications. The study was based on Slovenian health claims data of all outpatient prescriptions in 2018. Anticholinergic burden was evaluated using the Anticholinergic Cognitive Burden scale. Three age groups were analysed: children (≤18 years), adults (19–64 years) and older adults (≥65 years). Anticholinergic medications were prescribed to 29.8% of the participants; 7.6% were exposed to a clinically significant anticholinergic burden. The proportion of patients exposed to anticholinergic burden was highest in older adults (43.2%), followed by adults (25.8%) and children (20.7%). The most frequently prescribed medications with the highest anticholinergic activity were antipsychotics and medications for urinary diseases (42.8% and 40.2%, respectively). Medications with second highest activity were mostly antiepileptics (87.3%). Medications with possible anticholinergic activity included diverse therapeutic groups. Anticholinergic burden is highest in older adults but is also considerable among adults and children. Medications with anticholinergic activity belong to diverse therapeutic groups. Further research is needed on safe use of these medications in all age groups.

Từ khóa


Tài liệu tham khảo

Nishtala, P. S., Salahudeen, M. S. & Hilmer, S. N. Anticholinergics: theoretical and clinical overview. Expert. Opin. Drug. Saf. 15, 753–768 (2016).

UpToDate, electronic clinical resource tool, http://www.uptodate.com (2019).

West, T., Pruchnicki, M. C., Porter, K. & Emptage, R. Evaluation of anticholinergic burden of medications in older adults. J. Am. Pharm. Assoc. 53, 496–504 (2003).

Gray, S. L. et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern. Med. 175, 401–407 (2015).

Salahudeen, M. S. & Nishtala, P. S. Examination and Estimation of Anticholinergic Burden: Current Trends and Implications for Future Research. Drugs Aging 33, 305–313 (2016).

Marcum, Z. A. et al. Anticholinergic Use and Recurrent Falls in Community-Dwelling Older Adults: Findings From the Health ABC Study. Ann. Pharmacother. 49, 1214–1221 (2015).

Gamble, D. T. et al. Baseline anticholinergic burden from medications predicts incident fatal and non-fatal stroke in the EPIC-Norfolk general population. Int. J. Epidemiol. 47, 625–633 (2018).

Coupland, C. A. C. et al. Anticholinergic Drug Exposure and the Risk of Dementia: A Nested Case-Control Study. JAMA Intern Med 24 (2019).

Richardson, K. et al. Anticholinergic drugs and risk of dementia: case-control study. BMJ 25 (2018).

Fox, C. et al. Anticholinergic medication use and cognitive impairment in the older population: the medical research council cognitive function and ageing study. J. Am. Geriatr. Soc. 59, 1477–1483 (2011).

Steel, Z. et al. The global prevalence of common mental disorders: a systematic review and meta-analysis 1980–2013. Int. J. Epidemiol. 43, 476–493 (2014).

Landi, F. et al. Anticholinergic drug use and negative outcomes among the frail elderly population living in a nursing home. J. Am. Med. Dir. Assoc. 15, 825–829 (2014).

Madden, K., Hussain, K. & Tasker, R. C. Anticholinergic Medication Burden in Pediatric Prolonged Critical Illness: A Potentially Modifiable Risk Factor for Delirium. Pediatr. Crit. Care Med. 19, 917–924 (2018).

Hong, I. S. & Bishop, J. R. Anticholinergic use in children and adolescents after initiation of antipsychotic therapy. Ann. Pharmacother. 44, 1171–1180 (2010).

Madden, K., Burns, M. M. & Tasker, R. C. Differentiating Delirium From Sedative/Hypnotic-Related Iatrogenic Withdrawal Syndrome: Lack of Specificity in Pediatric Critical Care Assessment Tools. Pediatr. Crit. Care Med. 18, 580–588 (2017).

Campbell, N., Maidment, I., Fox, C., Khan, B. & Boustani, M. The 2012 update to the anticholinergic cognitive burden scale. J. Am. Geriatr. Soc 61(No. S1), S142–S143 (2013).

Boustani, M., Campbell, N., Munger, S., Maidment, I. & Fox, C. Impact of anticholinergics on the aging brain: a review and practical application. Aging Health 4, 311–320 (2008).

Duran, C. E., Azermai, M. & Vander Stichele, R. H. Systematic review of anticholinergic risk scales in older adults. Eur. J. Clin. Pharmacol. 69, 1485–1496 (2013).

Gorup, E., Rifel, J. & Petek Ster, M. Anticholinergic Burden and Most Common Anticholinergic-acting Medicines in Older General Practice Patients. Zdr. Varst. 57, 140–147 (2018).

Fox, C. et al. Effect of medications with anti-cholinergic properties on cognitive function, delirium, physical function and mortality: a systematic review. Age Ageing 43, 604–615 (2014).

Anderson, S. L. & Vande Griend, J. P. Quetiapine for insomnia: A review of the literature. Am. J. Health Syst. Pharm. 71, 394–402 (2014).

American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc 63, 2227–2246 (2015).

Trospium Chloride 20 mg Film-Coated Tablets. Summary of Product Characteristics, http://www.medicines.org.uk (2019).

Tolterodine tartrate 1 mg film-coated tablets. Summary of product characteristics, http://www.medicines.org.uk (2019).

Quetiapine 25mg film-coated tablets. Summary of product characteristics, http://www.medicines.org.uk (2019).

Salahudeen, M. S., Duffull, S. B. & Nishtala, P. S. Anticholinergic burden quantified by anticholinergic risk scales and adverse outcomes in older people: a systematic review. BMC Geriatr. 15, 31, https://doi.org/10.1186/s12877-015-0029-9 (2015).

Kouladjian, L., Gnjidic, D., Reeve, E., Chen, T. F. & Hilmer, S. N. Health Care Practitioners’ Perspectives on Deprescribing Anticholinergic and Sedative Medications in Older Adults. Ann. Pharmacother. 50, 625–636 (2016).

Slovenian national health insurance annual report 2015. Published 2016, http://www.zzzs.si (2019).

PCNE Newsletter. 2017, http://www.pcne.org/upload/files/174_PCNE_news_2016-4.pdf (2019).

Jazbar, J., Locatelli, I., Horvat, N. & Kos, M. Clinically relevant potential drug-drug interactions among outpatients: A nationwide database study. Res. Soc. Adm. Pharm. 14, 572–580, https://doi.org/10.1016/j.sapharm.2017.07.004 (2018).

Mardetko, N. & Kos, M. Introduction of therapeutic reference pricing in Slovenia and its economic consequences. Eur. J. Health Econ. 19, 571–584, https://doi.org/10.1007/s10198-017-0903-9 (2018).

Welsh, T. J., van der Wardt, V., Ojo, G., Gordon, A. L. & Gladman, J. R. F. Anticholinergic Drug Burden Tools/Scales and Adverse Outcomes in Different Clinical Settings: A Systematic Review of Reviews. Drugs Aging 35, 523–538, https://doi.org/10.1007/s40266-018-0549-z (2018).

Lozano-Ortega, G. et al. A review of published anticholinergic scales and measures and their applicability in database analyses. Arch Gerontol Geriatr, https://doi.org/10.1016/j.archger.2019.05.010 (2019).

West, T., Pruchnicki, M. C., Porter, K. & Emptage, R. Evaluation of anticholinergic burden of medications in older adults. J. Am. Pharm. Assoc. 53, 496–504, https://doi.org/10.1331/JAPhA.2013.12138 (2013).